There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DocGo (DCGO – Research Report) and Avadel Pharmaceuticals (AVDL – Research Report) with bullish sentiments.
DocGo (DCGO)
In a report released today, Ryan MacDonald from Needham maintained a Buy rating on DocGo, with a price target of $7.00. The company’s shares closed last Wednesday at $3.50, close to its 52-week low of $2.78.
According to TipRanks.com, MacDonald is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for DocGo with a $8.75 average price target, implying a 152.9% upside from current levels. In a report issued on April 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $6.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Avadel Pharmaceuticals (AVDL)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Avadel Pharmaceuticals, with a price target of $27.00. The company’s shares closed last Wednesday at $16.25.
According to TipRanks.com, Livnat is a 2-star analyst with an average return of
Avadel Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $24.50, representing a 54.2% upside. In a report released yesterday, Craig-Hallum also initiated coverage with a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DCGO:
- DocGo price target lowered to $6.50 from $8 at Stifel
- DocGo price target lowered to $9 from $10 at Canaccord
- DocGo signs extension, starts transition of asylum seeker contract with NYC HPD
- DocGo contract transition could remove overhang, says Canaccord
- DocGo’s Subsidiary Renews NYC Asylum Seeker Support Contract
